Prostaglandin D Synthase (β-Trace) in Meningeal Hemangiopericytoma

Department of Neuropathology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Modern Pathology (Impact Factor: 6.19). 04/2001; 14(3):197-201. DOI: 10.1038/modpathol.3880285
Source: PubMed


The level of prostaglandin D synthase (PGDS), a major protein constituent of cerebrospinal fluid (CSF), is altered in various brain diseases, including meningitis. However, its role in the brain remains unclear. PGDS is mainly synthesized in the arachnoid cells, the choroid plexus and oligodendrocytes in the central nervous system. Among brain tumors, meningiomas showed intense immunoreactivity to PGDS in the perinuclear region. Thus, PGDS has been considered a specific cell marker of meningioma. In this study, we examined 25 meningeal hemangiopericytomas (HPCs) and found that 16 of the tumors (64%) showed immunoreactivity for PGDS in the perinuclear region. For comparison, 15 meningiomas, 14 soft-tissue HPCs, 1 mesenchymal chondrosarcoma, 3 choroid plexus papillomas, and 7 oligodendrogliomas were also examined. Meningiomas showed positive immunoreactivity for PGDS in 13 cases (80%). Except for one case located at the sacrum, none of the other soft-tissue HPCs showed immunostaining for PGDS. Mesenchymal chondrosarcoma arises in the bones of the skull, and its histological pattern resembles that of HPC; however, it showed no immunoreactivity for PGDS. Neither choroid plexus papillomas nor oligodendrogliomas were immunopositive for PGDS. These findings suggest that meningeal HPCs may have a unique molecular phenotype that is distinct from that of the soft-tissue HPCs. The origin of meningeal HPCs may be more closely related to the arachnoid cells.

Download full-text


Available from: Masatou Kawashima, Mar 23, 2014
  • Source
    • "PGDS is an enzyme active in the production of prostaglandins (pro-inflammatory an anti-inflammatory molecules). Elevated expression of PGDS has been found in brain tumors, ovarian and breast cancer [50] [26], while hematopoietic PGDS has not been, to our knowledge, associated with leukemias. Viewing the rule as a whole, the absence of PGDS expression may be a part of the ''molecular signature'' reflecting either the general tissue type (leukocytes) or the specific, KIAA0128 (Septin 6) dependent, leukemic process. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Finding disease markers (classifiers) from gene expression data by machine learning algorithms is characterized by a high risk of overfitting the data due the abundance of attributes (simultaneously measured gene expression values) and shortage of available examples (observations). To avoid this pitfall and achieve predictor robustness, state-of-the-art approaches construct complex classifiers that combine relatively weak contributions of up to thousands of genes (attributes) to classify a disease. The complexity of such classifiers limits their transparency and consequently the biological insights they can provide. The goal of this study is to apply to this domain the methodology of constructing simple yet robust logic-based classifiers amenable to direct expert interpretation. On two well-known, publicly available gene expression classification problems, the paper shows the feasibility of this approach, employing a recently developed subgroup discovery methodology. Some of the discovered classifiers allow for novel biological interpretations.
    Full-text · Article · Sep 2004 · Journal of Biomedical Informatics
  • Source

    Full-text · Article ·
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The Immunohistochemistry of CD34 and a variety of antibodies in 61 cases of benign and malignant fusiform tumors was examined. The diagnosis were those of solitary fibrous tumor, gastrointestinal stromal tumors, smooth muscle tumors, fibrohistiocytic tumors, adipose tissue, perivascular and vascular tumors. The tumors showed fusiform cells, however their clinicopathological appearance and prognosis were different. The importance of immunohistochemistry and particularly of CD34 in the differential diagnosis of these tumors is discussed. Usando CD34 y otros anticuerpos, se examinaron inmunohistoquímicamente 61 casos de tumores fusocelulares benignos y malignos diagnosticados como tumor fibroso solitario, tumor del estroma gastrointestinal, tumores de músculo liso, fibrohistiocíticos, del tejido adiposo, perivasculares y vasculares. Todos mostraron histológicamente células fusiformes pero desde el punto de vista clínico, patológico y del pronóstico, representan entidades diferentes. Se discute la importancia de la inmunohistoquímica y específicamente de CD34 en el diagnóstico diferencial de estas neoplasias.
    Full-text · Article · Jan 2002
Show more